Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effects of Bexagliflozin Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin

NCT03115112 is registered in ClinicalTrials.gov with Theracos as lead sponsor.

NCT NCT03115112
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03115112 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Active-Controlled Study to Evaluate the Effects of Bexagliflozin Versus Sitagliptin in Subjects With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control by Metformin
Lead sponsor
Theracos
Phase
Phase 3
Overall status
Completed
Start date
October 12, 2017
Completion date
October 31, 2018
Enrollment
386 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus